Diabetic Eye Disease News and Research RSS Feed - Diabetic Eye Disease News and Research

Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.
Peek's smartphone eye examination tool could help tackle blindness

Peek's smartphone eye examination tool could help tackle blindness

The team behind Peek, the Portable Eye Examination Kit, are calling on the public to help provide a solution to avoidable blindness by increasing access to potentially life-changing new eye health testing equipment. [More]
Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham. [More]
New approach to measuring, correcting visual abnormalities

New approach to measuring, correcting visual abnormalities

A technique developed by astronomers seeking a clear view of distant objects in space is being intensively studied as a new approach to measuring and correcting visual abnormalities. [More]
Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal. [More]
Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

Research by Keck Medicine of USC ophthalmology scientists demonstrates that African Americans bear heavier burden of diabetic macular edema (DME), one of the leading causes of blindness in diabetic patients in the United States. [More]
ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology. [More]
Study reveals that color vision abnormalities increase with age

Study reveals that color vision abnormalities increase with age

​Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
People with diabetes at risk of developing diabetic macular edema during their lifetime

People with diabetes at risk of developing diabetic macular edema during their lifetime

Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study. [More]
Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

Cardiovascular complications and hypoglycemia (low blood sugar) were common nonfatal complications in adults 60 years of age and older with diabetes, according to a study published by JAMA Internal Medicine, a JAMA Network publication. [More]
Optic flow enables perception despite blur image

Optic flow enables perception despite blur image

Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry. [More]
Researchers work on stem cell treatments to halt vision loss caused by diabetic retinopathy

Researchers work on stem cell treatments to halt vision loss caused by diabetic retinopathy

Researchers at the Eugene and Marilyn Glick Eye Institute and the Indiana Center for Vascular Biology at Indiana University School of Medicine are on the cusp of perfecting stem cell treatments that would halt - and potentially reverse - vision loss caused by diabetic retinopathy. [More]
Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin. [More]
Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease. [More]
Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness [More]
Lucentis receives FDA approval for treatment of diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes. [More]
Researchers hope to use experiences of people with long-term T1D to benefit others

Researchers hope to use experiences of people with long-term T1D to benefit others

Researchers at Joslin Diabetes Center, supported by JDRF, have completed a study of 158 people who have lived with type 1 diabetes (T1D) for 50 years or more with eye examinations at Joslin over many decades of follow-up, and have concluded that a high proportion of this unique group of patients developed little to no diabetic eye disease over time. [More]
Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema. [More]
First comprehensive framework to close the gap on Indigenous eye health for Australians

First comprehensive framework to close the gap on Indigenous eye health for Australians

Presently Indigenous Australians suffer six times the blindness of mainstream Australians and 94 percent of vision loss in Indigenous Australians is unnecessary, preventable or treatable. [More]
JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease. [More]
JDRF initiates enrollment in metformin clinical study for type 1 diabetes

JDRF initiates enrollment in metformin clinical study for type 1 diabetes

JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D. [More]